The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Propofol and Midazolam in the Treatment of Refractory Status Epilepticus
Open accessAbstract
Summary: Purpose: To explore outcome differences between propofol and midazolam (MDL) therapy for refractory status epilepticus (RSE). Methods: Retrospective chart review of consecutive patients treated for RSE between 1995 and 1999. Results: We found 14 patients treated primarily with propofol and six with MDL. Propofol and MDL therapy achieved 64 and 67% complete clinical seizure suppression, and 78 and 67% electrographic seizure suppression, respectively. Overall mortality, although not statistically significant, was higher with propofol (57%) than with MDL (17%) (p = 0.16). Subgroup mortality data in propofol and MDL patients based on APACHE II (Acute Physiology and Chronic Health Evaluation) score did not show statistically significant differences except for propofol‐treated patients with APACHE II score ≥20, who had a higher mortality (p = 0.05). Reclassifying the one patient treated with both agents to the MDL group eliminated this statistically significant difference (p = 0.22). Conclusions: In our small sample of RSE patients, propofol and MDL did not differ in clinical and electrographic seizure control. Seizure control and overall survival rates, with the goal of electrographic seizure elimination or burst suppression rather than latter alone, were similar to previous reports. In RSE patients with APACHE II score ≥20, survival with MDL may be better than with propofol. A large multicenter, prospective, randomized comparison is needed to clarify these data. If comparable efficacy of these agents in seizure control is borne out, tolerance with regard to hemodynamic compromise, complications, and mortality may dictate the choice of RSE agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Treatment of refractory generalized status epilepticus with continuous infusion of midazolam
Parent, J. M., & Lowenstein, D. H. (1994) · Neurology · doi:10.1212/wnl.44.10.1837 · Cited by 116
Cited by
Guidelines for the Evaluation and Management of Status Epilepticus
Neurocritical Care Society Status Epilepticus Guideline Writing Committee, Brophy, G. M., Bell, R., Claassen, J., Alldredge, B., Bleck, T. P., Glauser, T., LaRoche, S. M., Riviello, J. J., Shutter, L., et al. (2012) · Neurocritical Care · doi:10.1007/s12028-012-9695-z · Cited by 1,623
Self-citationRefractory Status Epilepticus: Frequency, Risk Factors, and Impact on Outcome
Mayer, S. A., Claassen, J., Lokin, J., Mendelsohn, F., Dennis, L. J., & Fitzsimmons, B.-F. (2002) · Archives of Neurology · doi:10.1001/archneur.59.2.205 · Cited by 658
Claassen, J., Hirsch, L. J., Emerson, R. G., & Mayer, S. A. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.28501.x · Cited by 642
Status epilepticus: pathophysiology and management in adults
Chen, J. W., & Wasterlain, C. G. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70374-x · Cited by 504
EFNS guideline on the management of status epilepticus in adults
Meierkord, H., Boon, P., Engelsen, B., Göcke, K., Shorvon, S., Tinuper, P., & Holtkamp, M. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02917.x · Cited by 433
Metadata
- Authors
- Prasad, A., Worrall, B. B., Bertram, E. H., & Bleck, T. P.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2001-03-09
- Volume
- 42
- Issue
- 3
- Pages
- 380-386
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W1997921700
- Cited by
- 223
- References
- 1
- FWCI
- 7.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Propofol and Midazolam in the Treatment of Refractory Status Epilepticus. https://app.cochat.ai/papers/10.1046/j.1528-1157.2001.27500.x
- The paper
- Prasad, A., Worrall, B. B., Bertram, E. H., & Bleck, T. P. (2001). Propofol and Midazolam in the Treatment of Refractory Status Epilepticus. Epilepsia. https://doi.org/10.1046/j.1528-1157.2001.27500.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.